Sherry Aulin: Thanks, Chris. Before diving in, I want to take a moment to introduce a new member of our team, Chad Fugere, who is joining Xenon as our Vice President, Investor Relations. Many of you on the call will know Chad is an integral member of the Investor Relations team at Seagen, leading up to its $40 billion buyout by Pfizer. And prior to Seagen, Chad spent nearly two decades as a healthcare analyst on both the sell side and buy side. We're excited to welcome Chad and proud that Xenon continues to attract top talent across all areas of our business. Turning now to our financial results. Xenon is in the fortunate position of having a strong balance sheet to support our broad and robust plans for XEN1101 and other programs in our pipeline.